Klin Farmakol Farm. 2023;37(1):5-9 | DOI: 10.36290/far.2023.001

Current trends in pharmacotherapy of erectile dysfunction

David Čapka
Urologická klinika 3. LF UK v Praze a FNKV, Praha
Andrologická klinika, Praha

Penile erection is a complex physiological process that involves the integration of neural and vascular processes along with an adequate endocrine environment. Erectile dysfunction can affect psychosocial health and have a significant impact on the quality of life of patients and their partner. The article discusses an overview of medication-induced oral, intraurethral and topical treatments. The shift to really effective treatment was brought about by the pharmacotherapy of the end of the last century - i. e. PDE5-i. The adapted treatment strategy depends on invasiveness, efficacy, safety and price as well as on the patient's preferences. With treatment we can achieve a satisfactory effect and thus a satisfied sex life of the patient in more than 95 % of cases. Pharmacotherapy of erectile dysfunction should follow the recommended procedures available on the EAU website.

Keywords: erection, erectile dysfunction, pharmacotherapy.

Accepted: April 13, 2023; Published: April 21, 2023  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Čapka D. Current trends in pharmacotherapy of erectile dysfunction. Klin Farmakol Farm. 2023;37(1):5-9. doi: 10.36290/far.2023.001.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Gratzke C, et al. Anatomy, physiology, and pathophysiology of erectile dysfunction. J Sex Med. 2010;7:445. Go to original source... Go to PubMed...
    2. Feldman HA, et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol. 1994;151:54. Go to original source... Go to PubMed...
    3. EAU Guidelines. Edn. presented at the EAU Annual Congress Milan 2023. ISBN 978-94-92671-19-6.
    4. Isidori AM, et al. A critical analysis of the role of testosterone in erectile function: from pathophysiology to treatment-a systematic review. Eur Urol. 2014;65:99. Go to original source... Go to PubMed...
    5. Broul M, et al. Hodnocení erektilní dysfunkce po roboticky asistované radikální prostatektomii. Ces Urol. 2014; 18(4):324-333. Go to original source...
    6. Montorsi F, et al. Summary of the recommendations on sexual dysfunctions in men. J Sex Med. 2010;7:3572. Go to original source... Go to PubMed...
    7. Yuan J, et al. Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysis. Eur Urol. 2013;63:902. Go to original source... Go to PubMed...
    8. Hatzimouratidis K, et al. Pharmacotherapy for Erectile Dysfunction: Recommendations From the Fourth International Consultation for Sexual Medicine (ICSM 2015). J Sex Med. 2016;13:465. Go to original source... Go to PubMed...
    9. Lue TF. Erectile dysfunction. N Engl J Med. 2000;342:1802. Go to original source... Go to PubMed...
    10. Goldstein I, et al. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N Engl J Med. 1998;338:1397. Go to original source... Go to PubMed...
    11. Moncada I, et al. Efficacy of sildenafil citrate at 12 hours after dosing: re-exploring the therapeutic window. Eur Urol. 2004;46:357. Go to original source... Go to PubMed...
    12. Goldstein I, et al. Oral sildenafil in the treatment of erectile dysfunction. 1998. J Urol. 2002;167:1197. Go to original source... Go to PubMed...
    13. Goldstein I, et al. Efficacy and Safety of Sildenafil by Age in Men With Erectile Dysfunction. J Sex Med. 2016;13:852. Go to original source... Go to PubMed...
    14. Curran M, et al. Tadalafil. Drugs. 2003;63:2203. Go to original source... Go to PubMed...
    15. Bella AJ, et al. Tadalafil in the treatment of erectile dysfunction. Curr Urol Rep. 2003;4:472. Go to original source... Go to PubMed...
    16. Zhou Z, et al. Meta-Analysis of the Long-Term Efficacy and Tolerance of Tadalafil Daily Compared With Tadalafil On-Demand in Treating Men With Erectile Dysfunction. Sexual medicine. 2019;7:282. Go to original source... Go to PubMed...
    17. Paduch DA, et al. Effects of 12 weeks of tadalafil treatment on ejaculatory and orgasmic dysfunction and sexual satisfaction in patients with mild to severe erectile dysfunction: integrated analysis of 17 placebo-controlled studies. BJU Int. 2013;111:334. Go to original source... Go to PubMed...
    18. Gacci M, et al. Latest Evidence on the Use of Phosphodiesterase Type 5 Inhibitors for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia. Eur Urol. 2016;70:124. Go to original source... Go to PubMed...
    19. Keating GM, et al. Vardenafil: a review of its use in erectile dysfunction. Drugs. 2003;63:2673. Go to original source... Go to PubMed...
    20. Capogrosso P, et al. Time of onset of vardenafil orodispersible tablet in a real-life setting - looking beyond randomized clinical trials. Expert Rev Clin Pharmacol. 2017;10:339. Go to original source... Go to PubMed...
    21. Chung E, et al. A state of art review on vardenafil in men with erectile dysfunction and associated underlying diseases. Expert Opin Pharmacother. 2011;12:1341. Go to original source... Go to PubMed...
    22. Wang R, et al. Selectivity of avanafil, a PDE5 inhibitor for the treatment of erectile dysfunction: implications for clinical safety and improved tolerability. J Sex Med. 2012;9:2122. Go to original source... Go to PubMed...
    23. Goldstein I, et al. A randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of avanafil in subjects with erectile dysfunction. J Sex Med. 2012;9:1122. Go to original source... Go to PubMed...
    24. Corona G, et al. The safety and efficacy of Avanafil, a new 2 generation PDE5i: Comprehensive review and meta-analysis. Expert Opinion on Drug Safety. 2016;15:237. Go to original source... Go to PubMed...
    25. Zámečník L. Moderní léčba poruch erekce - co víme po dvaceti letech. Kapitoly z kardiologie pro praktické lékaře. 2018;10(1):24-27. ISSN 1803-7542.
    26. Bittner L. Manažersky dokonalá erekce. Acta Medicinae. 2016;5(11):70. ISSN 1805-398X.
    27. Nehra A, et al. Doporučení Princeton III Consensus pro léčbu erektilní dysfunkce a kardiovaskulárních onemocnění. Mayo Clin Proc. 2012;87:766. Go to original source... Go to PubMed...
    28. Vlachopoulos C, a kol. Erektilní dysfunkce u kardiovaskulárního pacienta. Eur Heart J. 2013;34:2034. Go to original source... Go to PubMed...
    29. Corona G, et al. The use of phosphodiesterase 5 inhibitors with concomitant medications. J Endocrinol Invest. 2008;31:799. Go to original source... Go to PubMed...
    30. Porst H, et al. SOP conservative (medical and mechanical) treatment of erectile dysfunction. J Sex Med. 2013;10:130. Go to original source... Go to PubMed...
    31. Cai T, et al. The intra-meatal application of alprostadil cream (Vitaros®) improves drug efficacy and patient's satisfaction: results from a randomized, two-administration route, cross-over clinical trial. Int J Impot Res. 2019;31:119. Go to original source... Go to PubMed...
    32. Kloner RA. Novel phosphodiesterase type 5 inhibitors: assessing hemodynamic effects and safety parameters. Clin Cardiol. 2004;27:I20. Go to original source... Go to PubMed...
    33. Padma-Nathan H, et al. An integrated analysis of alprostadil topical cream for the treatment of erectile dysfunction in 1732 patients. Urology. 2006;68:386. Go to original source... Go to PubMed...
    34. Shabsigh R, et al. Intracavernous alprostadil alfadex is more efficacious, better tolerated, and preferred over intraurethral alprostadil plus optional actis: a comparative, randomized, crossover, multicenter study. Urology. 2000;55:109. Go to original source... Go to PubMed...
    35. Eardley I, et al. Pharmacotherapy for erectile dysfunction. J Sex Med. 2010;7.524. Go to original source... Go to PubMed...
    36. Moriel EZ, et al. Sodium bicarbonate alleviates penile pain induced by intracavernous injections for erectile dysfunction. J Urol. 1993;149:1299. Go to original source... Go to PubMed...
    37. Duncan C, et al. Erectile dysfunction: a global review of intracavernosal injectables. World J Urol. 2019;37:1007. Go to original source... Go to PubMed...

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.